Chroma Therapeutics Ltd., from whom CTI licensed tosedostat, is facilitating drug supply for the trial.As the population of patients 65 years of age and older with AML continues to grow, there are a large number of patients who are not suitable for conventional intensive chemotherapy and for these patients there is a significant unmet need for an alternative therapy that is effective and well tol